EGFR and non-small cell lung carcinoma: In the patients with ICI‐naïve metastatic NSCLC, the lifileucel plus pembrolizumab regimen resulted in an encouraging ORR at 42.1% (8/19), an even higher rate at 58.3% (4/8) for patients with EGFR wild‐type and PD‐L1‐negative.